AB1261 THE ANALYSIS OF THE ONSET OF SYSTEMIC LUPUS ERYTHEMATOSUS IN PEDIATRIC POPULATION
Authors: R. Denisova, E. Alexeeva, T. Dvoryakovskaya, K. Isaeva, A. Chomakhidze, A. Mamutova, O. Lomakina, A. Fetisova, M. Gautier, K. Chibisova, I. Kriulin, E. Krekhova, I. Tsulukiya
Journal: Annals of the Rheumatic Diseases (2022)

Background Systemic lupus erythematosus (SLE) is characterized by multiple autoantibodies associated with a multisystem illness where any organ can be targeted. There are different classification criteria for SLE. Sensitivity and specificity of three criteria have been debated and may vary in different populations and clinical settings. Objectives We aim to evaluate the clinical and laboratory symptoms of the onset of systemic lupus erythematosus in pediatric population. Methods A total of 116 SLE patients (female –92, male-24) were included into the study. We analyzed the primary diagnosis, the time before identification the SLE, clinical and laboratory symptoms, their combination, and fulfilling the classification criteria of SLE. All data is presented as Me (IQR). Results The age of the onset of SLE was 13.3 (10.7, 15.2) years. 55/116 patients had other diagnosis before the verification of SLE, the time before the verification was 10 (5, 26) months. The loss of weigh was in 63(54%) of patients, fever – in 83(72%) (febrile – 57, subfebrile -26), adenopathy in 55(47%), malar rash – in 45(39%), discoid rash – in 19(16%), alopecia – in 19 (16%), photosensitivity – in 39(34%), oral ulcers – in 38 (33%), nazal ulcers – in 11(9.5%), arthritis – in 31(27%), pleuritis- in 18(16%), pericarditis- in 20(17%), renal disorder – in 52(47%), seizures- in 7(6%), psychosis – in 1(0.9%), myelitis – in 2(1.7%), peripheral neuropathy – in 3(2.6%), cranial neuropathy – in 2(1.7%), hemolytic anemia – in 59(51%), leukopenia- in 62(53%), thrombocytopenia- in 27(23%), ANA positivity – in 100(86%), anti-dsDNA antibody positivity – in 91(78%), antiphospholipid antibody positivity– in 27 (25%), direct Coombs’ test- in 22(19%). SELENA–SLEDAI Score was 13 (9, 20): low activity- in 14(12%) patients, moderate activity- in 23(20%), high activity – in 42(36%), very high activity – in 37(32%). 96 (83%) patients met the eligibility criteria ELAR/ACR 2019, 112(97%) – ACR criteria modified in 1997, 106(91%) – SLICC in 2012. Conclusion In this cohort, although all three criteria have sufficient. Some SLE patients with a clinical diagnosis lacked sufficient number of criteria. Disclosure of Interests Rina Denisova Speakers bureau: Speaker for Roche, AbbVie, MSD, Novartis., Grant/research support from: Financial grants from Roche, Pfizer, Centocor, Sanofi and Novartis., Ekaterina Alexeeva Speakers bureau: Speaker for Roche, AbbVie, Bristol-Myers, Squibb, MSD, Novartis and Pfizer., Grant/research support from: Financial grants from Roche, Pfizer, Centocor, Eli Lilly, AbbVie, Bristol-Myers Squibb, MSD, Sanofi, Amgen and Novartis., Tatyana Dvoryakovskaya Speakers bureau: Speaker for Roche, AbbVie, Bristol-Myers, Squibb, MSD, Novartis and Pfizer., Grant/research support from: Financial grants from Roche, Pfizer, Centocor, Eli Lilly,AbbVie, Bristol-Myers Squibb, MSD, Amgen and Novartis., Ksenia Isaeva Grant/research support from: Financial grants from Roche, Novartis and Sanofi., Aleksandra Chomakhidze: None declared, Anna Mamutova Speakers bureau: Speaker for Novartis., Grant/research support from: Financial grants from Eli Lilly., Olga Lomakina Grant/research support from: Financial grants from Pfizer, Eli Lilly., Anna Fetisova Grant/research support from: Financial grants from Amgen., Marina Gautier: None declared, Kristina Chibisova: None declared, Ivan Kriulin Speakers bureau: Speaker for Novartis., Elizaveta Krekhova Speakers bureau: Speaker for Novartis., Irina Tsulukiya: None declared